Viking Therapeutics Inc (VKTX)

[PaPaGriz]

Info taken from Seeking Alpha and the NGMBio website.

NGM Biopharmaceuticals on deck for IPO....The biopharma firm has seven candidates in its pipeline. Lead drug is Phase 2b-stage NGM282, an engineered version of human hormone FGF19, for the treatment of NASH. Candidate #2 is Phase 1b-stage NGM313 for NASH and type 2 diabetes....

NGM282, an engineered version of human hormone FGF19 that is administered through a once-daily subcutaneous injection, has demonstrated the ability to rapidly improve NASH and reverse liver fibrosis in clinical and preclinical studies. We believe the combination of breadth, magnitude and speed of effect demonstrated by NGM282 in these studies results in an agent that, if ultimately approved, could provide a needed medicine for physicians to treat NASH patients with moderate to advanced fibrosis. We have tested NGM282 in over 400 subjects, including more than 150 NASH patients, and we expect to initiate a Phase 2b clinical trial in NASH patients in the first quarter of 2019. NGM282 is wholly-owned, and it is not subject to our collaboration with Merck.

Seems to be putting downward pressure on VKTX, GALT, GILD and more.